Statement of Principles concerning malignant neoplasm of the salivary gland (Balance of Probabilities) (No. 103 of 2023)

Administered by Department of Veterans' Affairs

Legislation au F2023L01431 In force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

STATEMENT OF PRINCIPLES CONCERNING

MALIGNANT NEOPLASM OF THE SALIVARY GLAND

(BALANCE OF PROBABILITIES) (NO. 103 OF 2023)

 

VETERANS' ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

  1. This is the Explanatory Statement to the Statement of Principles concerning malignant neoplasm of the salivary gland (Balance of Probabilities) (No. 103 of 2023).

Background

2.             The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA), repeals Instrument No. 58 of 2015 (Federal Register of Legislation No. F2015L00261) determined under subsections 196B(3) and (8) of the VEA concerning malignant neoplasm of the salivary gland.

3.             The Authority is of the view that on the sound medical-scientific evidence available it is more probable than not that malignant neoplasm of the salivary gland and death from malignant neoplasm of the salivary gland can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(3) of the VEA a Statement of Principles concerning malignant neoplasm of the salivary gland (Balance of Probabilities) (No. 103 of 2023).  This Instrument will in effect replace the repealed Statement of Principles.

Purpose and Operation

4.             The Statement of Principles will be applied in determining claims under the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

5.             The Statement of Principles sets out the factors that must exist, and which of those factors must be related to the following kinds of service rendered by a person:

 eligible war service (other than operational service) under the VEA;

 defence service (other than hazardous service and British nuclear test defence service) under the VEA;

 peacetime service under the MRCA,

before it can be said that, on the balance of probabilities, malignant neoplasm of the salivary gland or death from malignant neoplasm of the salivary gland is connected with the circumstances of that service.  The Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

6.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 10 May 2022 concerning malignant neoplasm of the salivary gland in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

7.             The contents of this Instrument are in similar terms as the repealed Instrument.  Comparing this Instrument and the repealed Instrument, the differences include:

  • adopting the latest revised Instrument format, which commenced in 2015;
  • specifying a day of commencement for the Instrument in section 2;
  • revising the definition of 'malignant neoplasm of the salivary gland' in subsection 7(2);
  • revising the factors in Section 9 that must as a minimum exist before it can be said that on the balance of probabilities that malignant neoplasm of the salivary gland or death from malignant neoplasm of the salivary gland are connected with the circumstances of a veteran's relevant service. The revision is required to reflect advances in sound medical scientific evidence that have occurred since the repealed Statement of Principles was made;
  • new factor in subsection 9(4) concerning having an infection with human immunodeficiency virus; and
  • new definitions of 'MRCA' and 'VEA' in Schedule 1  Dictionary.

Incorporation

8.             The definition of "cumulative equivalent dose" contained in the Schedule 1 – Dictionary incorporates the Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017.  This writing is incorporated pursuant to subsection 14(b) of the Legislation Act 2003.

9.             A copy of this document is available to any person on the website of the Repatriation Medical Authority at www.rma.gov.au or from the Repatriation Medical Authority, Level 8, 480 Queen St, Brisbane, Queensland 4000, by contacting the Registrar on telephone (07) 3815 9404.

Consultation

10.         Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to malignant neoplasm of the salivary gland in the Government Notices Gazette of 10 May 2022, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, the Military Rehabilitation and Compensation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority in relation to the investigation.

Human Rights

11.         This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.  A Statement of Compatibility with Human Rights follows.

Finalisation of Investigation

12.         The determining of this Instrument finalises the investigation in relation to malignant neoplasm of the salivary gland as advertised in the Government Notices Gazette of 10 May 2022.

References

13.         A list of references relating to the above condition is available on the Authority's website at: www.rma.gov.au. Any other document referred to in this Statement of Principles is available on request to the Repatriation Medical Authority at the following address:

              

Email:    info@rma.gov.au

Post:      The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001


Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 103 of 2023

Kind of Injury, Disease or Death: Malignant neoplasm of the salivary gland

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(3) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).  Part XIA of the VEA requires the determination of these instruments outlining the factors connecting particular kinds of injury, disease or death with service such being determined solely on the available sound medical-scientific evidence.

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission and the Military Rehabilitation and Compensation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have malignant neoplasm of the salivary gland;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • outlines the factors which the current sound medical-scientific evidence indicates must exist before it can be said that, on the balance of probabilities, malignant neoplasm of the salivary gland is connected with the circumstances of eligible service rendered by a person, as set out in clause 5 of the Explanatory Statement;
  • replaces Instrument No. 58 of 2015; and
  • reflects developments in the available sound medical-scientific evidence concerning malignant neoplasm of the salivary gland which have occurred since that earlier instrument was determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICESCR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICESCR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members;
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD); and
  • ensuring that those rights "will be exercised without discrimination of any kind as to race, colour, sex, language, religion, political or other opinion, national or social origin, property, birth or other status" (Art 2, ICESCR).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Statement of Principles concerning malignant neoplasm of the salivary gland (Balance of Probabilities) (No. 103 of 2023) was enacted in 2023 to address the need for an updated framework regarding the connection between malignant neoplasm of the salivary gland and military service. This legislative instrument was determined by the Repatriation Medical Authority under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). The primary policy objective is to facilitate the assessment and determination of claims for veterans and other eligible persons suffering from malignant neoplasm of the salivary gland by specifying the circumstances in which medical treatment and compensation can be extended. This instrument replaces the previous Statement of Principles No. 58 of 2015, incorporating the latest sound medical-scientific evidence to improve the medico-scientific quality of outcomes under the VEA and MRCA. It also ensures compatibility with human rights, promoting the rights of veterans and their dependents without discrimination. The Statement of Principles sets out the factors that must exist, and which of those factors must be related to eligible war service, defence service, and peacetime service before it can be said that, on the balance of probabilities, malignant neoplasm of the salivary gland or death from malignant neoplasm of the salivary gland is connected with the circumstances of that service. This legislative instrument not only aims to provide clarity and consistency in the assessment of claims but also reflects advances in sound medical-scientific evidence that have occurred since the previous statement was made. The new factors, such as the inclusion of human immunodeficiency virus infection, highlight the ongoing efforts to ensure that the instrument remains relevant and accurate in light of new evidence.

Scope and Application

The Statement of Principles concerning malignant neoplasm of the salivary gland (Balance of Probabilities) (No. 103 of 2023) applies to claims under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. It specifies the circumstances under which malignant neoplasm of the salivary gland or death from such a neoplasm is deemed to be connected with eligible war service, defence service, or peacetime service. The Instrument outlines the factors that must exist, and which of those factors must be related to the relevant service, to establish a connection on the balance of probabilities. This determination replaces the previously repealed Instrument No. 58 of 2020, reflecting updated medical-scientific evidence. The Authority, having examined the available evidence, concluded that it is more probable than not that the specified neoplasm can be linked to particular service circumstances. This Instrument incorporates the latest revised Instrument format and includes new definitions and factors, such as the inclusion of an HIV infection as a relevant factor. The Instrument does not derogate from human rights and promotes several rights, including the right to social security and adequate living standards, as well as the right to the highest attainable standard of health. A Statement of Compatibility with Human Rights confirms its compatibility with international human rights instruments. The scope and application of this legislation are confined to the Australian jurisdiction, specifically addressing the eligibility criteria for veterans and their dependents to claim benefits related to malignant neoplasm of the salivary gland. This is achieved through the integration of the latest medical-scientific evidence into the legislative framework, ensuring that the assessment of claims is both accurate and up-to-date. The Instrument is designed to assist claimants, the Repatriation Commission, and the Military Rehabilitation and Compensation Commission in evaluating claims effectively and transparently, thereby upholding the rights of affected individuals under international human rights standards.

Key Provisions

The Statement of Principles concerning malignant neoplasm of the salivary gland (Balance of Probabilities) (No. 103 of 2023) (the Instrument) outlines the circumstances in which malignant neoplasm of the salivary gland and death from such neoplasm can be related to particular kinds of service under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). This Instrument, determined under subsection 196B(3) of the VEA, sets out the factors that must exist, and which of those factors must be related to eligible war service, defence service, or peacetime service, before it can be said that, on the balance of probabilities, malignant neoplasm of the salivary gland or death from such neoplasm is connected with the circumstances of that service (Section 9). The Instrument also incorporates the latest sound medical-scientific evidence, including the definition of "cumulative equivalent dose" (Section 7), and specifies new factors, such as the presence of human immunodeficiency virus infection (subsection 9(4)). The obligations under this Act include facilitating claimants in making, and the Repatriation Commission and the Military Rehabilitation and Compensation Commission in assessing, claims under the VEA and the MRCA, respectively. It also facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal. The Instrument serves to specify the circumstances in which medical treatment and compensation can be extended to eligible persons who have malignant neoplasm of the salivary gland, and it replaces Instrument No. 58 of 2015, reflecting developments in the available sound medical-scientific evidence. There are no specific offences, penalties, or civil/criminal consequences outlined for breach of this Instrument. However, the determination of this Instrument finalises the investigation in relation to malignant neoplasm of the salivary gland as advertised in the Government Notices Gazette of 10 May 2022. The Instrument is assessed as being a technical instrument that improves the medico-scientific quality of outcomes under the VEA and the MRCA. It is compatible with human rights and does not derogate from any human rights, promoting the human rights of veterans, current and former Defence Force members, and their dependents. A Statement of Compatibility with Human Rights follows, confirming that this Legislative Instrument does not derogate from any human rights and promotes several human rights, including the right to social security and the right to an adequate standard of living.

Legal classification tags

Area of Law
Veterans' Law
Instrument
Explanatory Statement
Concepts
Definitions & Interpretation
Licensing & Registration
Human Rights Law

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.